Despite current advances in therapies and the gradual decline in breast cancer-related mortality, metastasis is the major determinant of breast cancer survival. The treatment regimens for breast cancer metastasis are ...

Neurodegenerative diseases such as Frontotemporal Dementia (FTD), and Amyotrophic Lateral Sclerosis (ALS), also known as Motor Neuron Disease (MND), have limited therapeutics available, placing a high demand on healthcare ...

Alzheimer’s disease (AD) is a neurodegenerative disease that is pathologically characterized by abnormal deposition of extracellular amyloid plaques and intraneuronal neurofibrillary tangles. The deposition of these ...

Motor neurone disease (MND) is a fatal human neurodegenerative disorder. The most common form of MND is amyotrophic lateral sclerosis (ALS). MND is characterised by the progressive destruction of motor neurons in the central ...

Amyloid precursor protein (APP) is neuroprotective in traumatic brain injury (TBI). Treatment with soluble amyloid precursor protein (sAPP) can rescue motor and cognitive deficits following TBI in mouse and rat models ...

Fibrosis is one of the leading causes of death that may affect all organs in the human body. All forms of fibrosis are characterized by fibrotic scarring resulting from replacement of normal tissue with extracellular matrix ...

Traumatic brain injury (TBI) represents a major cause of disability and death worldwide with sustained neuro-inflammation and autophagy dysfunction contributes to cellular damage. Stimulator of interferon genes (STING)-induced ...

AD is a complex disease, involving the perturbation of multiple interrelated biological pathways. Despite being the most common form of neurodegenerative disease, with the number of patients expected to increase drastically, ...

The airway epithelium is an important barrier interface that protects the lungs against environmental insults and pathogens. Airway epithelial cells are increasingly recognized as key regulators of lung immune homeostasis ...

Glucocorticoids (GCs) remain the frontline treatment in the management of chronic inflammatory diseases, as they are the most potent and effective anti-inflammatory agents available so far. However, impaired responses ...